Quantitative analysis of 5α-reductase inhibitors in DU145 cells using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and high-performance liquid chromatography/tandem mass spectrometry

Journal of Mass Spectrometry

Volumn 39, Issue 7, 2004, Pages 762-769

  Kang, Min Jung ^a   Mathur, Sonal ^a   Hartmann, Rolf W ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

5 reductase inhibitors; High performance liquid chromatography tandem mass spectrometry; Matrix assisted laser desorption ionization time of flight mass spectrometry; Methyl ester prodrug; Quantification

Indexed keywords

CARBOXYLIC ACIDS; DESORPTION; ENZYMES; ESTERS; GAS PERMEABLE MEMBRANES; IONIZATION; LASER BEAM EFFECTS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY;

MATRIX-ASSISTED LASER DESORPTION; MEMBRANE PERMEABILITY;

CELLS;

ESTER DERIVATIVE; N (DICYCLOHEXYL)ACETYLPIPERIDINE 4 BENZYLIDENE 4 CARBOXYLIC ACID; PRODRUG; STEROID 5ALPHA REDUCTASE INHIBITOR; UNCLASSIFIED DRUG; BENZOIC ACID DERIVATIVE; ENZYME INHIBITOR; N-(DICYCLOHEXYL)ACETYLPIPERIDINE-4-BENZYLIDENE-4-CARBOXYLIC ACID; PIPERIDINE DERIVATIVE; STEROID 5ALPHA REDUCTASE;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL FREE SYSTEM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MONITORING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; LINEAR SYSTEM; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MEMBRANE PERMEABILITY; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE ANALYSIS; RELIABILITY; REPRODUCIBILITY; SOLID PHASE EXTRACTION; STATISTICAL ANALYSIS; STRUCTURE ACTIVITY RELATION; TANDEM MASS SPECTROMETRY; ADENOCARCINOMA; CHEMISTRY; DRUG ANTAGONISM; ENZYMOLOGY; MASS SPECTROMETRY; METHODOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ADENOCARCINOMA; BENZOIC ACIDS; CELL LINE, TUMOR; ENZYME INHIBITORS; HUMANS; MALE; PIPERIDINES; PRODRUGS; PROSTATIC NEOPLASMS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 4043091273     PISSN: 10765174     EISSN: None     Source Type: Journal    
DOI: 10.1002/jms.647     Document Type: Article

References (26)

1. Keetch DW, Andriole GL. Medical therapy for benign prostatic hyperplasia. Am. J. Roentgenol. 1995; 164: 11.
2. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS, Vaughan ED, Pappas F, Taylor A, Binkowitz B, Ng J. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N. Engl. J. Med. 1992; 327: 1185.
3. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (Dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 434.
4. Russell DW, Wilson JD. Steroid 5α-reductase. Annu. Rev. Biochem. 1994; 63: 25.
5. Wilson JD, Griftra JE, Russell DW. Steroid 5 alpha-reductase 2 deficiency. Endocrinol. Rev. 1993; 14: 577.
6. Geller J, Albert J, Lopez D Geller S, Niwayama G. Comparison of androgen metabolites in benign prostatic hypertrophy (BPH) and normal prostate. J. Clin. Endocrinol. 1976; 43: 486.
7. Labrie F, Belanger A. Simard J, Labrie C, Dupont A. Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapy. Cancer 1993; 71: 1059.
8. Andersson S, Russell DW. Structural and biochemical properties of cloned and expressed human and rat steroid 5 alpha-reductases. Proc. Natl. Acad. Sci. USA 1990; 87: 3640.
9. Sudduth SL, Koronkowski MJ. Finasteride: the first 5 alpha-reductase inhibitor. Pharmacotherapy 1993; 13: 325.
10. Jones CD, Audia JE, Lawhorn DE, MaQuaid LA, Neubauer BL, Pike AJ, Pennington PA, Stamm NB, Toomey RE, Hirsch KS. Nonsteroidal inhibitors of human type I steroid 5α-reductase. J. Med. Chem. 1993; 36: 421:
11. Takami H, Koshimura H, Kishibayashi N, Ishii A, Nonaka H, Aoyama S, Kase H, Kumazawa T. Indole derivatives as a new class of steroid 5α-reductase inhibitors. J. Med. Chem. 1996; 39: 5047.
12. Smith ECR, McQuaid LA, Goode RL, McNulty AM, Neubauer BL, Rocco VP, Audia JE. Synthesis and 5α-reductase inhibitory activity of 8-substituted benzo[f]quinolinones derived from palladium mediated coupling reactions. Bioorg. Med. Chem. Lett. 1998; 8: 395.
13. Abell AD, Brandt M, Levy MA, Holt DA. Preparation and biological activity of tricyclic non-steroidal inhibitors of human steroid 5α-reductase. J. Chem. Soc., Perkin Trans. 1 1997; 1663.
14. Guarna A, Machetti F, Occhiato EG, Scarpi D. Benzo[c]quinolizin-3-ones: a novel class of potent and selective nonsteroidal inhibitors of human steroid 5α-reductase 1. J. Med. Chem. 2000; 43: 3718.
15. Lesuisse D, Gourvest J-F, Albert E, Doucet B, Hartmann C, Lefrançois J-M, Tessier S, Tric B, Teutsch G. Biphenyls as surrogates of the steroidal backbone. Part 2: discovery of a novel family of non-steroidal 5α-reductase inhibitors. Bioorg. Med. Chem. Lett. 2001; 11: 1713.
16. Sawada K, Okada S, Kuroda A, Watanabe S, Sawada Y, Tanaka H. 4-(Benzoylindolizinyl)butyric acids; novel nonsteroidal inhibitors of steroid 5α-reductase. III. Chem. Pharm. Bull. 2001; 49: 799.
17. Fujita T, Matsumoto Y, Kimura T, Yokota S, Sawada M, Majima M, Ohtani Y, Kumagai Y. Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5α-reductase inhibitor, in normal subjects treated with single or multiple doses. J. Clin. Pharmacol. 2002; 54: 283.
18. Hiipakka RA, Zhang H-Z, Dai W, Dai Q, Liao S. Structure-activity relationships for inhibition of human 5α -reductases by polyphenols. Biochem. Pharmacol 2002; 63: 1165.
19. Picard F, Schulz T, Hartmann RW. 5-Phenyl substituted 1-methyl-2-pyridones and 4′-substituted biphenyl-4-carboxylic acids. Synthesis and evaluation as inhibitors of steroid-5α -reductase type 1 and 2. Bioorg. Med. Chem. 2002; 10: 437.
20. Picard F, Barassin S, Mokhtarian A, Hartmann RW. Synthesis and evaluation of 2′-substituted 4-(4′-carboxy- or 4′-carboxymethylbenzylidene)-N-acylpiperidines: highly potent and in vivo active steroid 5α-reductase type 2 inhibitors. J. Med. Chem. 2002; 45: 3406.
21. Salem OIA, Schulz T, Hartmann RW. Synthesis and biological evaluation of 4-(4-(alkyl- and phenylaminocarbonyl)benzoyl)benzoic acid derivatives as non-steroidal inhibitors of steroid 5α-reductase isozymes 1 and 2. Arch. Pharm. Pharm. Med. Chem. 2002; 2: 83.
22. Reichert W, Jose J, Hartmann RW. 5α-Reductase in intact DU145 cells: evidence for isozyme I and evaluation of novel inhibitors. Arch. Pharm. Pharm. Med. Chem. 2000; 333: 201.
23. Kang M-J, Tholey A, Heinzle E. Quantitation of low molecular mass substrates and products of enzyme catalyzed reactions using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Rapid Commun. Mass Spectrom. 2000; 14: 1972.
24. Kang M-J, Tholey A, Heinzle E. Application of automated matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for the measurement of enzyme activities. Rapid Commun. Mass Spectrom. 2001; 15: 1327.
25. Leis HJ, Fauler G, Raspotnig G, Windischhofer W. Quantitative determination of the angiotensin-converting enzyme inhibitor lisinopril in human plasma by stable isotope dilution gas chromatography/negative ion chemical ionization mass spectrometry. Rapid Commun. Mass Spectrom. 1998; 12: 1591.
26. Wittmann C, Heinzle E. MALDI-TOF MS for quantification of substrates and products in cultivations of Corynebacterium glutamicum. Biotechnol. Bioeng. 2001; 72: 642.